Peptide Drug Conjugates Poised for $1.5B Market by 2031 as Oncology Focus Accelerates
Peptide drug conjugate market projected to reach $1.5 billion by 2031 with 14%+ CAGR, driven by targeted oncology therapies and innovative linker technologies from major biotech players.
NVSBCYCPEPGclinical trialspharmaceutical innovation